

Hear from expert industry speakers at Oligonucleotide Therapeutics and Delivery 2021

SMI reports: Speakers confirmed at Oligonucleotide Therapeutics and Delivery Conference, which will convene in London on 22nd and 23rd September.

LONDON, LONDON BRIDGE , UNITED KINGDOM, May 11, 2021 /EINPresswire.com/ -- [Oligonucleotide therapeutics](https://www.einpresswire.com/oligonucleotide-therapeutics) - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA.

The Oligonucleotide Therapeutics and [Delivery](#) conference is here to keep you updated with discussions that will be centered around improving targeted therapy uniting the field's biggest players to share their opinions.

This year's agenda will encompass key drivers and hot topics of the industry including recent advances in oligonucleotide therapeutics, optimising oligonucleotide development strategies, clinical advances of RNAi therapy and emerging delivery solutions.

Registration is live on the website and an early bird saving of £200 will be applied to bookings made before 28th May 2021: www.oligonucleotide.co.uk/einpr2

Plus, an interactive half day pre-conference workshop:

Target Discovery for RNA Therapeutics

Workshop Leader: Martin Akerman, Chief Technology Officer, Envisagenics

Featured 2021 speakers include:

A promotional poster for the 'Oligonucleotide Therapeutics & Delivery 2021' conference. The poster features a central red rectangular box with white text. Above the box, it says 'SMI Group Proudly Presents'. The main title 'Oligonucleotide Therapeutics & Delivery' is in a large, bold font, followed by the dates '22 - 23 September 2021' and the location 'London, UK'. At the bottom of the red box, it says 'Register at: www.oligonucleotide.co.uk'. The background of the poster is a light blue-grey color with a decorative border of red and black spheres, resembling a molecular structure. Below the poster, the text 'Oligonucleotide Therapeutics and Delivery 2021' is written in a smaller font.

Chair for 2021

Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

- David Evans, Chief Scientific Officer, Sirnaomics, Inc
- Stefan Vonhoff, VP Chemistry & Manufacturing, NOXXON Pharma AG
- Adrien Weingartner, Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics AG
- Tom Baladi, Postdoctoral Research Fellow, AstraZeneca
- Maria Luisa Pineda, CEO and Co-founder, Envisagenics
- Ekkehard Leberer, Senior Director, R&D Alliance Management, Sanofi
- Michelle Lynn Hall, Senior Director, Novel Therapeutic Modalities, Eli Lilly and Company
- Jimmy Weterings, Principal Scientist, AstraZeneca
- Meiling Li, Senior Scientist, F. Hoffmann-La Roche Ltd.

The event brochure with the agenda and speaker line-up is available to download from the website; those interested in attending can register at: www.oligonucleotide.co.uk/einpr2

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu
SMi Group
02078276088
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/540807642>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.